A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders.
about
Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trialCardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youthRecommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region.Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic reviewSafety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: a 26-week, open-label, continuation study.Treatment of neurolept-induced tardive dyskinesiaManagement of schizophrenia in children and adolescents: focus on pharmacotherapy.Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis.The effect of antidepressants and antipsychotics on weight gain in children and adolescents.Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.Child and adolescent schizophrenia: pharmacological approachesPredictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders StudyEarly Detection and Treatment of Psychosis: The Bern Child and Adolescent Psychiatric Perspective
P2860
Q34486230-E0B4EC63-152E-40B8-A404-A93D347CA2D7Q34613195-D202FD88-B555-4A67-A3F8-693D45AAF783Q35128405-E6EAA8A6-A202-43AC-A1C6-55747F0E57CDQ35984960-29F4D8FB-E130-4687-9FB8-ADA41AA8A502Q36026845-8FA32D2C-B554-401F-93D9-087870109B0EQ36186039-D5AEBD9D-4EA7-423E-8E9A-6F1C27554B93Q37187450-7F871F64-A676-410E-9643-7561E640E37DQ37198420-525760EF-B263-44B5-A17E-3C4C4752CB38Q37833061-09C57526-36D0-4ED8-81B0-F22079DA6223Q38090490-0B66E713-C6BE-4C18-8487-2D840E109B7AQ38153030-F2492B23-56EB-4005-9671-73674E58B3AEQ38504263-ECB8D54A-9D78-4815-9FA5-0CE5DE9C018EQ38657158-616EA26D-BF91-4A40-867E-637393BE9A75Q56675062-9A7D017F-F2FD-4065-A4BA-2CCF42E0DCE4Q57164581-8489474E-D925-4849-A953-7BBB6B0048B9Q59050567-F824DD30-AFCF-48C8-AA7E-1AE1E37CE9E0
P2860
A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
A prospective 12-week study of ...... izophrenia spectrum disorders.
@en
A prospective 12-week study of ...... izophrenia spectrum disorders.
@nl
type
label
A prospective 12-week study of ...... izophrenia spectrum disorders.
@en
A prospective 12-week study of ...... izophrenia spectrum disorders.
@nl
prefLabel
A prospective 12-week study of ...... izophrenia spectrum disorders.
@en
A prospective 12-week study of ...... izophrenia spectrum disorders.
@nl
P2093
P356
P1476
A prospective 12-week study of ...... izophrenia spectrum disorders.
@en
P2093
Baerbel Gierow
Benno Graf Schimmelmann
Claudia Mehler-Wex
Constanze Schulze-zur-Wiesch
Eberhard Meyer
Eginhard Koch
Hans Henning Flechtner
Joachim Maier
Martin Lambert
Michael Schulte-Markwort
P304
P356
10.1089/CAP.2007.0048
P577
2007-12-01T00:00:00Z